Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review

Mário Morais‐Almeida(CUF Porto Hospital), Jean Bousquet(Charité - Universitätsmedizin Berlin)

International Archives of Allergy and Immunology

January 1, 2020

10.1159/000509057

Cited by 105

Related Papers

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

|Allergy|2004|1.1k

Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study

|Allergy|2011|1.1k

Rhinitis and onset of asthma: a longitudinal population-based study

|The Lancet|2008|613

Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma

|Clinical & Experimental Allergy|2004|520

Asthma in adults and its association with chronic rhinosinusitis: The GA <sup>2</sup> LEN survey in Europe

|Allergy|2011|485